Muhammad Y. Sheikh

Rifaximin Treatment in Hepatic Encephalopathy

Nathan M. Bass, Kevin D. Mullen, Arun J. Sanyal et al. · New England Journal of Medicine · 2010 · 1.3K citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy

Kevin D. Mullen, Arun J. Sanyal, Nathan M. Bass et al. · Clinical Gastroenterology and Hepatology · 2013 · 203 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13